Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Sales reflect continued strong growth in oncology and vaccines
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
